首页|沙库巴曲缬沙坦钠片治疗腹膜透析合并慢性心衰患者的临床研究

沙库巴曲缬沙坦钠片治疗腹膜透析合并慢性心衰患者的临床研究

扫码查看
目的:沙库巴曲缬沙坦钠片治疗腹膜透析合并慢性心衰患者的临床研究.方法:选取2021年5月—2023年4月收治的60例腹膜透析合并慢性心衰患者为研究对象,随机数字表法分为对照组与治疗组各30例,对照组给予腹膜透析+基础治疗,治疗组给予腹膜透析+沙库巴曲缬沙坦钠片,对比两组疗效、肾功能、心功能及不良反应.结果:治疗组治疗后NT-proBNP、hs-CRP、Scr较对照组低,血钾较对照组高(P<0.05);治疗组治疗后LVEDD、LVESD指标较对照组低(P<0.05);治疗后两组不良反应发生率差异无统计学意义(P>0.05).结论:沙库巴曲缬沙坦钠片可改善患者血液指标,改善心功能,且安全性较高.
Clinical Study of Sacubitril Valsartan Sodium Tablets in the Treatment of Peritoneal Dialysis Patients with Chronic Heart Failure
Objective:Clinical study of sacubitril valsartan sodium tablets in the treatment of peritoneal dialysis patients with chronic heart failure.Methods:Sixty patients with chronic heart failure complicated by peritoneal dialysis admitted from May 2021 to April 2023 were selected as the study subjects.They were randomly divided into a control group and a treatment group of 30 cases each using a random number table method.The control group received peritoneal dialysis+basic treatment,while the treatment group received peritoneal dialysis+sacubitril valsartan sodium tablets.The therapeutic effects,renal function,heart function,and adverse reactions of the two groups were compared.Results:After treatment,the NT proBNP,hs CRP,and Scr in the treatment group were lower than those in the control group,and the blood potassium was higher than those in the control group(P<0.05);The LVEDD and LVESD indicators in the treatment group were lower than those in the control group after treatment(P<0.05);There was no statistically significant difference in the incidence of adverse reactions between the two groups after treatment(P>0.05).Conclusion:Sacubitril valsartan sodium tablets can improve patient blood indicators,improve heart function,and have high safety.

Sacubitril valsartan sodium tabletsPeritoneal dialysisChronic heart failureHeart functionAdverse reaction incidence rate

吴康全、黄玉英、陶青玲、林周徒

展开 >

广东医科大学附属第二医院肾内科(广东湛江 524000)

沙库巴曲缬沙坦钠片 腹膜透析 慢性心衰 心功能 不良反应发生率

湛江市科技计划项目

2021B01074

2024

黑龙江医药
黑龙江省药品审评认证中心

黑龙江医药

影响因子:0.597
ISSN:1006-2882
年,卷(期):2024.37(4)
  • 8